Company profile: BlossomHill Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies focused on oncology and autoimmune disorders, including FDA-approved repotrectinib (AUGTYRO) for ROS1+ NSCLC, crizotinib (XALKORI) and lorlatinib (LORBRENA), and pipeline candidates elzovantinib (TPX-0022) and TPX-0046, both in Phase 1 studies.
Products and services
- Crizotinib (XALKORI): An FDA-approved drug engineered by Dr. Cui during her Pfizer tenure, branded as XALKORI, with established regulatory approval and origin in Pfizer’s development program
- Lorlatinib (LORBRENA): An FDA-approved drug resulting from Dr. Cui's work at Pfizer, marketed as LORBRENA, evidencing regulatory clearance and development lineage from Pfizer research efforts
- Repotrectinib (AUGTYRO): An FDA-approved drug for locally advanced or metastatic ROS1+ NSCLC, branded as AUGTYRO, authorized specifically for ROS1-positive non-small cell lung cancer indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BlossomHill Therapeutics
Confluence Life Sciences
HQ: United States
Website
- Description: Provider of rational drug design-based discovery and development of mechanistically novel kinase inhibitors for human and animal health care, targeting key signal transduction enzymes involved in regulating cancer growth and survival and modulating chronic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confluence Life Sciences company profile →
Oncolytics Biotech
HQ: Canada
Website
- Description: Provider of oncolytic virus therapeutics for a broad range of cancers, developing Pelareorep, a nonpathogenic oncolytic virus that selectively replicates in cancer cells to generate immune responses, enhance oncology treatments, and extend patient survival.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncolytics Biotech company profile →
Courier Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions, including a protein therapeutics platform aimed at making cancer immunotherapy safer and more efficacious, with potential in autoimmune and inflammatory diseases; AI-driven drug discovery offerings such as the Opal Computational Platform, Target Discovery, and Logica; and development of investigational therapies like OPL-0401 for diabetic retinopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Courier Therapeutics company profile →
Orega Biotech
HQ: France
Website
- Description: Provider of immunotherapeutic monoclonal antibodies for cancer, including IPH5201, a humanized CD39 blocking antibody that inhibits adenosine production and is in Phase 2 trials for non-small cell lung cancer, and a novel preclinical human-mouse cross-reactive blocking antibody that improves the efficacy of anti-PD-1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orega Biotech company profile →
Hawaii Biotech
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on R&D of prophylactic vaccines for infectious diseases, including recombinant subunit vaccines (dengue, West Nile, Zika, tick-borne flaviviruses), viral hemorrhagic fevers (Crimean-Congo), and coronaviruses (SARS-CoV-2, pan-beta). Offers the GPI-0100 adjuvant, a protein production platform for vaccine development, and small molecule therapeutics for anthrax intoxication and botulism (BoNT type A).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hawaii Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BlossomHill Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BlossomHill Therapeutics
2.2 - Growth funds investing in similar companies to BlossomHill Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BlossomHill Therapeutics
4.2 - Public trading comparable groups for BlossomHill Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →